Cytokinetics (NASDAQ: CYTK) shares have risen in price by more than 50%, leading investors and traders across the sector to become more interested in the company. This article tells you all of the key information you need to know before you invest in CYTK stock.
If you want to invest in Cytokinetics shares, and you want to find out the key information you need to inform your investment, you have come to the right article. We explain what the company is, why it is rising in value, and the best places to buy CYTK stock in the UK and elsewhere.
Scroll down to the section directly below to find out the best platforms to buy, sell and trade Cytokinetics stock, as chosen by our team of experienced analysts.
How & where to buy CYTK shares online
Simply click on one of the options below, fill out some basic details to sign up, then fund your account. After this, you will be able to buy the number of shares you want:
eToro is one of the world's leading multi-asset trading platforms offering some of the lowest commission and fee rates in the industry. It's social copy trading features make it a great choice for those getting started.
Financial company driven by technology and offering all-in-one self-directed investment platform that provides excellent user experience.
What is Cytokinetics?
It is a late-stage biopharmaceutical company that was incorporated in 1997 in South San Francisco, California.
It is focussed on discovering, developing, and commercialising muscle activators and inhibitors as potential treatments for debilitating diseases, and the company is currently developing several small molecule drug candidates primarily engineered to increase muscle function and contractility.
Its most notable drug candidates are Omecamtiv Mecarbil – a novel cardiac myosin activator in a Phase III clinical trial – and Reldesemtiv – a novel fast skeletal muscle troponin activator in a Phase II clinical trial to treat spinal muscular atrophy and amyotrophic lateral sclerosis.
The company has jumped in value following the announcement that its Phase 2 clinical trial for its experimental hypertrophic cardiomyopathy treatment yielded positive results.
Should I buy CYTK stock?
If you believe in the company’s investment credentials, and you think its treatments can forge a path to commercialisation, buying now could be a good way to speculate on future price accretion.
However, investing always carries risk, and this is especially true of biopharmaceutical companies. There are many opportunities for things to go wrong, so if you are averse to risk, you may be better off looking elsewhere.
CYTK price target 2021
Our Cytokinetics price forecast is as follows: a 12-month high of $41, with a median of $34 and a low of $21.